Guided Therapeutics

Guided Therapeutics Quick Ratio

The Quick Ratio (Acid Test) of Guided Therapeutics (GTHP) as of Nov 5, 2026 is 0.04. In the previous year, Quick Ratio (Acid Test) was 0.05 — a change of -24.45% (lower).

Quick Ratio

0.04

YoY

-24.45%

Last updated:

Quick Ratio (Acid Test) of Guided Therapeutics is 2025 0.04 . Quick Ratio (Acid Test) of Guided Therapeutics was 2024 0.05 . It decreases by -24.45% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics Stock analysis

What does Guided Therapeutics do? Guided Therapeutics, Inc. develops medical devices focused on cancer detection using biophotonics. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device for cervical cancer screening and triage. LuViva analyzes reflected and fluorescent light after scanning the cervix with light, offering an alternative to conventional tests. The firm targets healthcare providers and clinics seeking point-of-care solutions for cervical cancer detection. LuViva is designed for two main applications: as a screening tool for early detection of cervical cancer and precancers, and as a triage method to reduce unnecessary follow-up procedures. The company focuses on selling and marketing this device to medical facilities, emphasizing its painless, non-invasive nature and point-of-care functionality. Guided Therapeutics conducts limited clinical studies using its biophotonic technology to support the device's efficacy. The business model centers on the commercialization of LuViva, with the company developing prototypes and conducting clinical studies to validate its biophotonic detection method. Guided Therapeutics aims to position LuViva as a standard in cervical cancer screening, targeting healthcare providers who prioritize non-invasive, efficient diagnostic tools. The firm's revenue comes from the sale of LuViva devices and related services to medical institutions. Guided Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guided Therapeutics stock

Quick Ratio (Acid Test) of Guided Therapeutics is 0.04 in 2025.

Quick Ratio (Acid Test) of Guided Therapeutics changed from 0.05 to 0.04, representing a -24.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Guided Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Guided Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Guided Therapeutics

All Key Metrics — Guided Therapeutics